45
Participants
Start Date
January 16, 2008
Primary Completion Date
April 21, 2014
Study Completion Date
April 21, 2014
bortezomib
Given IV
dexamethasone
Given orally
melphalan
Given IV
thalidomide
Given orally
cytogenetic analysis
Performed on baseline and post transplant bone marrow specimens
fluorescence in situ hybridization
Performed on baseline and post transplant bone marrow specimens
laboratory biomarker analysis
Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
questionnaire administration
Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
autologous hematopoietic stem cell transplantation
Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
peripheral blood stem cell transplantation
Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
City of Hope Medical Center, Duarte
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER